ommended screening, defined as receipt of prostate-specific antigen (PSA) testing or mammography in individuals with a life expectancy of less than 10 years. 6 This cutoff was chosen based on previous reports. 1,2 Receipt of PSA testing was coded as performed if men answered yes to the question, "Have you ever had a PSA test?" and answered "Within the past year" to the question, "How long has it been since you had your last PSA test?" Receipt of mammography was coded as performed if women answered yes to the question, "Have you ever had a mammogram?" and "Within the past year" to the question, "How long has it been since you had your last mammogram?" Men who underwent PSA testing owing to a previous diagnosis of prostate cancer were excluded. Those previously diagnosed with breast cancer or prostate cancer were also excluded. A total of 149 514 individuals were identified (weighted n = 43 586 000). For all point estimates, 95% CIs and P values were calculated using the Complex Samples Package for SPSS (SPSS, Inc). The prevalence of self-reported screening in the past year was estimated for 2012 and quantified for each state. With the state as the unit of analysis, Pearson correlation coefficient was used to test the association between nonrecommended screenings for prostate cancer and breast cancer. Complex sample multivariable logistic regression models assessed the odds of nonrecommended screening for prostate cancer and breast cancer.
All statistical analyses were performed using SPSS, version 21, and the R statistical package (R Foundation for Statistical Computing), with a 2-sided significance set at P < .05. Data analysis was conducted from July 27, 2014, to October 30, 2015. Henry Ford Hospital Institutional Review Board approval was waived in accordance with institutional regulation when dealing with deidentified, previously collected data. 
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A, Unadjusted percentages of any nonrecommended screening. B, Unadjusted percentages of nonrecommended prostate cancer screening. C, Unadjusted percentages of nonrecommended breast cancer screening in individuals 65 years or older. Figure  5 and Table  5 ). In multivariable analysis, the state was independently associated with nonrecommended screening for both prostate cancer and breast cancer (P < .001 for both).
Discussion | Overall, the rate of nonrecommended screening for prostate cancer and breast cancer was high, seen in 15.7% of individuals 65 years or older. Significant state-by-state variation in the rate of nonrecommended screening was observed. Moreover, nonrecommended screening at the state-by-state level had a correlation of 40% between the 2 forms of screening (P = .01). Therefore, a state with a high rate of nonrecommended screening for prostate cancer is likely to have a high rate of nonrecommended screening for breast cancer and vice versa. To our knowledge, our study is the first to report the extent and variation of nonrecommended screening across states, fluctuating from 11.6% (95% CI, 10.4%-13.1%) in Colorado to 20.2% (95% CI, 17.9%-22.7%) in Georgia. Efforts should be deployed to reduce nonrecommended screening in states with a high rate of nonrecommended screening. This effort may avoid significant harms to many individuals and improve the cost efficiency of screening initiatives. Limitations of the study include the possible overestimation of life expectancy owing to unmeasured comorbidities, as well as the potential inclusion of some men and women previously diagnosed, treated, or observed for prostate cancer and breast cancer.
